Sarepta Therapeutics

Recent news

• Rating change
  Analysts' Opinions Are Mixed on These Healthcare Stocks: Vericel (VCEL), Sarepta Therapeutics (SRPT) and Neumora Therapeutics, Inc. (NMRA)
  TipRanks · 2026/7/28
• Rating change
  A Quick Look at Today's Ratings for Sarepta Therapeutics(SRPT.US), With a Forecast Between $5 to $38
  Market Newswire · 2026/8/7
• Wedbush Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating, Maintains Target Price $35
  Market Newswire · 2026/10/1
• Rating change
  Mizuho Securities Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating, Maintains Target Price $31
  Market Newswire · 2026/7/10
• Rating change
  J.P. Morgan Maintains Sarepta Therapeutics(SRPT.US) With Hold Rating, Raises Target Price to $23
  Market Newswire · 2026/9/2
• J.P. Morgan Maintains Sarepta Therapeutics(SRPT.US) With Hold Rating, Announces Target Price $20
  Market Newswire · 2026/9/30
• Rating change
  RBC Capital Maintains Sarepta Therapeutics(SRPT.US) With Hold Rating, Cuts Target Price to $19
  Market Newswire · 2026/6/18
• Rating change
  Evercore Maintains Sarepta Therapeutics(SRPT.US) With Hold Rating, Raises Target Price to $19
  Market Newswire · 2026/5/15
• Rating change
  Morgan Stanley Maintains Sarepta Therapeutics(SRPT.US) With Hold Rating, Maintains Target Price $25
  Market Newswire · 2026/7/27
• Citi Maintains Sarepta Therapeutics(SRPT.US) With Sell Rating, Maintains Target Price $13
  Market Newswire · 2026/9/28
• Rating change
  Needham Maintains Sarepta Therapeutics(SRPT.US) With Sell Rating
  Market Newswire · 2026/9/28
• Rating change
  J.P. Morgan Remains a Hold on Sarepta Therapeutics (SRPT)
  TipRanks · 2026/9/2
• Rating change
  Evercore Maintains Sarepta Therapeutics(SRPT.US) With Hold Rating, Maintains Target Price $19
  Market Newswire · 2026/8/10
• William Blair Initiates Sarepta Therapeutics(SRPT.US) With Hold Rating
  Market Newswire · 2026/9/29
• Rating change
  Barclays Maintains Sarepta Therapeutics(SRPT.US) With Hold Rating, Maintains Target Price $20
  Market Newswire · 2026/8/8
• Rating change
  Wolfe Research Upgrades Sarepta Therapeutics(SRPT.US) to Buy Rating, Announces Target Price $27
  Market Newswire · 2026/7/9
• Rating change
  H.C. Wainwright Reaffirms Their Sell Rating on Sarepta Therapeutics (SRPT)
  TipRanks · 2026/5/7
• Rating change
  J.P. Morgan Maintains Sarepta Therapeutics(SRPT.US) With Hold Rating
  Market Newswire · 2026/9/15
• Rating change
  J.P. Morgan Maintains Sarepta Therapeutics(SRPT.US) With Hold Rating, Announces Target Price $19
  Market Newswire · 2026/5/19
• H.C. Wainwright Maintains Sarepta Therapeutics(SRPT.US) With Sell Rating, Maintains Target Price $5
  Market Newswire · 2026/10/5

Headlines are aggregated automatically and are not independently verified or edited by our team.